Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Background: Prostate cancer (PCa) is the most common malignancy in men and in the absence of any effective treatments available.
Methods: For the development of potential anticancer agents, 24 kinds of naftopidil-based arylpiperazine derivatives containing the bromophenol moiety were synthesized and characterized by using spectroscopic methods. Their pharmacological activities were evaluated against human PCa cell lines (PC-3 and LNCaP) and a-adrenergic receptors (a-ARs; α, α, and α-ARs). The structure-activity relationship of these designed arylpiperazine derivatives was rationally explored and discussed.
Results: Among these derivatives, 3c, 3d, 3h, 3k, 3o, and 3s exhibited the most potent activity against the tested cancer cells, and some derivatives with potent anticancer activities exhibited better a-AR subtype selectivity than others did (selectivity ratio > 10).
Conclusion: This work provided a potential lead compound for the further development of anticancer agents for PCa therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s43440-019-00041-w | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!